Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorRobert, Laia
dc.contributor.authorDiego, Laura
dc.date.accessioned2018-06-21T11:25:00Z
dc.date.available2018-06-21T11:25:00Z
dc.date.issued2017-12
dc.identifier.citationRobert L, Diego L. Novetats terapèutiques 2017. Butll Inf Ter. 2017 Des;28(10):75-81.
dc.identifier.issn1579-9441
dc.identifier.urihttp://hdl.handle.net/11351/3558
dc.descriptionNew drugs; Naloxegol; Opicapona; Mepolizumab; Reslizumab
dc.description.abstractThis article revise the evidence of four new drugs. Naxolegol, a new opioid antagonist to the opioid-induced constipated treatment; opicapona, a new inhibitor of catechol-O-methyltransferase to the Parkinson disease treatment, and finally mepolizumab and reslizumab, two new monoclonal antibodies to the treatment of severe eosinophilic asthma.
dc.language.isocat
dc.publisherDepartament de Salut
dc.publisherServei Català de la Salut
dc.relation.ispartofseriesButlletí d'informació terapèutica;28(10)
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceScientia
dc.subjectParkinson, Malaltia de - Tractament
dc.subjectAsma - Tractament
dc.subjectRestrenyiment - Tractament
dc.subject.meshConstipation
dc.subject.mesh/drug therapy
dc.subject.meshParkinson Disease
dc.subject.meshAsthma
dc.titleNovetats terapèutiques 2017
dc.typeinfo:eu-repo/semantics/article
dc.subject.decsestreñimiento
dc.subject.decs/tratamiento farmacológico
dc.subject.decsenfermedad de Parkinson
dc.subject.decsasma
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliationCentre d'Informació de Medicaments de Catalunya (CedimCat), Barcelona, Spain
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record